Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02357225 · ClinicalTrials.gov registry record · Early Phase 1
A Pilot Study of Pyridostigmine in Pompe Disease
A Early Phase 1 study, sponsored by University of Florida.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT02357225 is a Early Phase 1 study that was terminated before completion, run by University of Florida. The registered enrollment target is 2 participants.
The verdict
NCT02357225, a Early Phase 1 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Pyridostigmine is an acetylcholinesterase inhibitor, which degrades acetylcholine at the neuromuscular junction. Based on recent studies, pyridostigmine may be an effective adjuvant treatment for people with Pompe disease, as it increases the functional impact of this neurotransmitter. Hypothesis: the use of pyridostigmine in Pompe disease will improve transmission of acetylcholine across the neuromuscular junction, skeletal muscle function, respiratory function, and quality of life.
Interventions
- DRUG Pyridostigmine Bromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2015-08 |
| Est. Completion | 2018-01-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02357225
The ClinicalTrials.gov registry entry for NCT02357225 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pyridostigmine Bromide is the first listed.
NCT02357225 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02357225 about?
NCT02357225 is a clinical study titled "A Pilot Study of Pyridostigmine in Pompe Disease". Pyridostigmine is an acetylcholinesterase inhibitor, which degrades acetylcholine at the neuromuscular junction. Based on recent studies, pyridostigmine may be an effective adjuvant treatment for people with Pompe disease, as it increases the functional impact of this neurotransmitter. Hypothesis: ...
What is the current status of trial NCT02357225?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2015-08. Estimated completion is 2018-01-01.
What interventions are being tested in trial NCT02357225?
The interventions under investigation include: Pyridostigmine Bromide (DRUG).
Who is sponsoring clinical trial NCT02357225?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.